Arisaph Pharmaceuticals

Arisaph Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 1999. The company specializes in developing therapies for cancer, cardiovascular diseases, and diabetes. Its product portfolio includes dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators, plaque reducers, and tumor-activated pro-soft drugs. Arisaph employs advanced drug discovery platforms to create differentiated medicines that selectively target validated disease pathways, aiming to address significant unmet medical needs in the cardiometabolic and oncology sectors.